September 13th 2021
Brian Helfand, MD, PhD, and Steven Finkelstein, MD, FACRO, provide insight on the results and clinical implications of the EMPIRE-1 trial in prostate cancer.
August 24th 2021
In this program, George Ansstas, MD, and Firas B. Badin, MD, discuss a recently published paper on ctDNA for analysis of immunotherapy efficacy in individual patients with solid tumor malignancies.
August 20th 2021
In this program, D. Ross Camidge, MD, PhD, and Alexander Spira, MD, PhD, discuss a recently published paper on the anti-HER3 monoclonal antibody seribantumab in the treatment of tumor samples with oncogenic NRG1 fusions.
August 9th 2021
In this journal club-like program, Sara A. Hurvitz, MD, and Steven E. Vogl, MD, discuss a recently published paper about third-line treatments for HER2-positive breast cancer and provide insight about its implications for clinical practice.